Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krystal BiotechFRA:4KB -1.96%59 EV-to-EBITDA is 50.04 as of Jul. 26, 2026, which is 43% above its 10-year median of 35.06. GuruFocus rates FRA:4KB with a GF Score™ of 59/100 and a GF Value™ of €268.15 (Fairly Valued). The stock has 2 warning signs investors should review. Among 404 Biotechnology companies, Krystal Biotech ranks worse than 84.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Krystal Biotech's enterprise value is €7,970.1 Mil.
Krystal Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €159.3 Mil. Therefore, Krystal Biotech's EV-to-EBITDA for today is 50.04.
The historical rank and industry rank for Krystal Biotech's EV-to-EBITDA or its related term are showing as below:
FRA:4KB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -99.42 Med: 35.06 Max: 530.84
Current: 48.95
During the past 10 years, the highest EV-to-EBITDA of Krystal Biotech was 530.84. The lowest was -99.42. And the median was 35.06.
FRA:4KB's EV-to-EBITDA is ranked worse than 84.9% of 404
companies
in the Biotechnology industry
Industry Median: 11.82
vs FRA:4KB: 48.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Krystal Biotech's PE Ratio (TTM) for today is calculated as:
Krystal Biotech's share price for today is €284.40.
Krystal Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.419.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Krystal Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs TECH, SMMT, ARWR: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Krystal Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's EV-to-EBITDA falls into.
Krystal Biotech's current Enterprise Value is €7,970.1 Mil.
Krystal Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €159.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a EV-to-EBITDA of 50.04 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Krystal Biotech. This is 43% above median its historical median of 35.06. According to the industry distribution chart, Krystal Biotech ranks #343 out of 404 companies in the Biotechnology industry, placing it in the top 84.9%.
Is Krystal Biotech's EV-to-EBITDA too high?
Krystal Biotech's current EV-to-EBITDA of 50.04 is 43% above median its 10-year median of 35.06. The Biotechnology industry median EV-to-EBITDA is 11.82. Krystal Biotech's value of 50.04 is 323.4% above this industry median. Based on the distribution chart, Krystal Biotech ranks #343 out of 404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Krystal Biotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's EV-to-EBITDA compare to TECH and SMMT?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #343 out of 404 companies for EV-to-EBITDA. This places Krystal Biotech in the lower half of its industry. The industry median EV-to-EBITDA is 11.82. Krystal Biotech's value of 50.04 is 323.4% above this benchmark. While the company's 10-year median is 35.06 vs. the industry median of 11.82, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.82, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current EV-to-EBITDA of 50.04 is 323.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Krystal Biotech. For the Biotechnology industry, the median EV-to-EBITDA is 11.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current EV-to-EBITDA is 50.04, which is 43% above median its own 10-year median of 35.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Fairly Valued. The stock's GF Value™ is €268.15, compared to a current price of €284.40 — trading 6.1% above its estimated fair value. The current EV-to-EBITDA is 50.04, which is 43% above median its 10-year median of 35.06 and 323.4% above the Biotechnology industry median of 11.82. Krystal Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current EV-to-EBITDA is 50.04 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €284.40 is trading 6.1% above its estimated GF Value™ of €268.15.
GuruFocus considers Krystal Biotech to be Fairly Valued.
Key valuation signals for FRA:4KB:
EV-to-EBITDA: 50.04 (43% above median its 10-year median of 35.06)
GF Value™: €268.15 vs. price of €284.40 (6.1% above fair value)
Industry Position: 323.4% above the Biotechnology median (#343 of 404)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
59GF Score
Get the complete analysis for FRA:4KB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
